Biopharmaceutical News and Research

RSS

PhoreMost and POLARISqb announce a multi-target collaboration to investigate next-generation cancer therapies

PhoreMost Limited and Polaris Quantum Biotech (POLARISqb) today announced a collaboration to study oncology targets currently considered undruggable.

From PhoreMost 6 Jan 2022

Optimizing bioprocessing with Raman spectroscopy

In this interview, News-Medical talks to Justin Moretto, Life Science Product Manager at Endress+Hauser Optical Analysis, about how Raman spectroscopy can be used in bioprocessing and the benefits this entails.

From Endress+Hauser 15 Dec 2021

Driving up immunity at tumor site may help enhance immunotherapy treatments

Driving up the immune response at the site of a cancer tumor with nanotechnology may help enhance immunotherapy treatments in advanced stages of the disease, new research in mice suggests.

14 Dec 2021

Positive results from Phase 3 study of Medicago’s plant-based COVID-19 vaccine candidate announced

Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline today announce positive efficacy and safety results from the global Phase 3 placebo-controlled efficacy study of Medicago’s plant-based COVID-19 vaccine candidate in combination with GSK’s pandemic adjuvant, conducted in over 24,000 subjects, adults 18 years and above, across six countries.

9 Dec 2021

Lunaphore to host inaugural Spatial Biology Week™ virtual meeting

Lunaphore today announced the events and activities planned around the inaugural Lunaphore Spatial Biology Week™, taking place virtually December 6-10, 2021.

From Lunaphore 7 Dec 2021

Protein found in rattlesnake venom used for making a drug candidate to modulate blood clotting

Researchers in Brazil and Belgium have developed a molecule of pharmaceutical interest from collinein-1, a protein found in rattlesnake venom.

1 Dec 2021

SBIR grant awarded to develop treatment for alcoholic liver disease-associated hepatorenal syndrome

The Institute of Human Virology (IHV) at the University of Maryland School of Medicine and MitoPower LLC were awarded an SBIR (Small Business Innovation Research) grant of up to $6.5 million over five years from the National Institutes of Health's National Institute on Alcohol Abuse and Alcoholism.

9 Nov 2021

Researchers use suction method to deliver SARS-CoV-2 DNA vaccine in lab tests

Rutgers researchers studying COVID-19 have created a new way to deliver DNA molecules into skin cells, using a suction technique similar to the ancient healing practice of cupping.

6 Nov 2021

Yokogawa Acquires Insilico Biotechnology, Developer of Innovative Bioprocess Digital Twin Technology - Enabling solutions for biopharmaceutical development and production -

Yokogawa announces that it has acquired all shares of Insilico Biotechnology AG (“Insilico”), a Stuttgart, Germany-based developer and provider of bioprocess software and services.

From Yokogawa Electric Corporation 3 Nov 2021

Waters and Sartorius partner to help bioprocess scientists accelerate clone selection and process development

Waters Corporation and Sartorius announced today they will partner to provide bioprocess experts with direct access to high-quality mass spectrometry (MS) data to accelerate the speed and improve the accuracy of biopharmaceutical process development.

From Sartorius 3 Nov 2021

Interferon beta-1a plus remdesivir not superior to remdesivir alone in hospitalized COVID-19 patients

A clinical trial has found that treatment with the immunomodulator interferon beta-1a plus the antiviral remdesivir was not superior to treatment with remdesivir alone in hospitalized adults with COVID-19 pneumonia.

18 Oct 2021

Developing New Technology for the Encapsulation of mRNA-Based Vaccines in Lipid Nanoparticles (LNPs)

NewsMed speaks to KNAUER about the company’s background, its range of specialisms and its pioneering work to facilitate the largescale production of LNPs while meeting the stringent regulations and exacting demands of the biopharmaceutical industry.

From KNAUER Wissenschaftliche Geräte GmbH 14 Oct 2021

New Maternal and Child Health Research Institute launched to improve national health in Singapore

The SingHealth Duke-NUS Maternal and Child Health Research Institute was launched at KK Women's and Children's Hospital (KKH) today by Masagos Zulkifli, Singapore's Minister for Social and Family Development and Second Minister for Health.

8 Oct 2021

Experts address questions on psoriasis patients’ true needs and wellbeing

Almirall S.A., a global biopharmaceutical company focused on skin health, has hosted a scientific session during the 30th EADV Congress which addressed the need and importance to focus on patient wellbeing in real-life clinical practice.

8 Oct 2021

RedShift BioAnalytics Celebrates Opening of StructIR Scientific Services Lab with the Launch of the StructIR Lab Grant Program

RedShift BioAnalytics announced the opening of their scientific services lab, StructIR Lab.

From RedShiftBio 7 Oct 2021

The new FlowCam® LO improves particle characterization in drug development

Yokogawa Fluid Imaging Technologies announces the release of the FlowCam® LO, the first and only light obscuration instrument with imaging capabilities.

From Yokogawa Fluid Imaging Technologies, Inc. 29 Sep 2021

Research paves the way for advances in the treatment of many brain disorders

Bristol-led research has identified specific drug targets within the neural circuits that encode memories, paving the way for significant advances in the treatment of a broad spectrum of brain disorders.

16 Sep 2021

New RDCA-DAP program launches to accelerate rare disease treatment innovation

The Rare Disease Cures Accelerator-Data and Analytics Platform initiative officially launched its next phase on Tuesday establishing itself as the leading platform to accelerate rare disease treatment innovation.

15 Sep 2021

Phase I clinical study evaluates safety and pharmacokinetics of ExeVir's COVID-19 neutralizing antibody

ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that the first subjects have been dosed in a Phase I clinical study of XVR011, its llama-derived antibody for the treatment and prevention of COVID-19.

19 Aug 2021

Atlas Antibodies acquires evitria

Atlas Antibodies has agreed to acquire evitria, a world leader in transient recombinant antibody expression in CHO cells. This transformative acquisition brings together a leading provider of highly validated research antibodies and a front-runner in the field of custom recombinant antibody expression.

From Atlas Antibodies 28 Jul 2021